Comparative Pharmacology
Head-to-head clinical analysis: KEPPRA versus NEURONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEPPRA versus NEURONTIN.
KEPPRA vs NEURONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.
None Documented
None Documented
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjustment required in renal disease.
Terminal elimination half-life is 5–7 hours in patients with normal renal function; in elderly or those with renal impairment, half-life may be prolonged up to 132 hours; requires dose adjustment for creatinine clearance <60 mL/min.
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
Renal elimination as unchanged drug: >90%; 0.3% is excreted in feces; biliary elimination is negligible.
Category C
Category C
Antiepileptic
Antiepileptic